Invited discussant abstracts 993Pd, 994PD and 995PD
| Date | 28 September 2014 |
| Event | ESMO 2014 |
| Session | Head and neck cancer |
| Topics | Anticancer Agents Thyroid Cancer Head and Neck Cancers Therapy Biological Therapy |
| Presenter | Lisa Licitra |
| Authors |
L. Licitra
|
View the abstracts discussed:
- Association of human papillomavirus (HPV) and p16 status with efficacy and safety data in the phase III radiotherapy (RT)/cetuximab (cet) registration trial for locoregionally advanced squamous cell carcinoma of the head and neck (LASCCHN)
- Clinical activity of the oral selective inhibitor of nuclear export (SINE) selinexor (KPT-330) in patients with head & neck squamos cell carcinoma (HN-SCC)
- Phase II study of lenvatinib (LEN), a multi-targeted tyrosine kinase inhibitor, in patients (pts) with all histologic subtypes of advanced thyroid cancer (differentiated, medullary and anaplastic)